On April 22, 2014 Hookipa Biotech AG, a biotech company pioneering a new class of vaccines, reported the award of a major grant from the Austrian Research Promotion Agency (Forschungs-Förderungs-Gesellschaft, FFG), the leading public funding agency for translational research in Austria (Press release, Hookipa Biotech, APR 22, 2014, View Source [SID:1234513401]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A EUR 3.38 million support is given for the second year of a multi-year vaccine development project. The grant will be used to further progress the development of Hookipa´s lead product candidate, HB101, a vaccine against cytomegalovirus (CMV) that is currently in advanced pre-clinical testing.

"We have made a very significant progress with our CMV vaccine candidate, and we would like to thank FFG for its continuous support of this important project", commented Dr. Katherine Cohen, CEO of Hookipa Biotech AG.